Title:
MK2 ACTIVATING COMPOUNDS FOR USE IN TREATING VASCULAR LEAK AND ENDOTHELIAL BARRIER DISORDERS
Document Type and Number:
WIPO Patent Application WO/2022/104097
Kind Code:
A3
Abstract:
Provided herein are MK2 activators, and compositions comprising an MK2 activator, for the treatment of a vascular disorder or an endothelial barrier disorder in a patient in need thereof, whereby the MK2 activator has a molecular weight below 1000 Da and binds to a binding pocket located on the C-lobe domain and C -terminal Regulatory Domain of MK2. Also provided are methods of treating a vascular disorder or an endothelial barrier disorder in a patient by administering to the patient an MK2 activator.
Inventors:
TSAIOUN KATYA (US)
KAYYALI USAMAH (US)
VILLOUTREIX BRUNO (FR)
KAYYALI USAMAH (US)
VILLOUTREIX BRUNO (FR)
Application Number:
PCT/US2021/059191
Publication Date:
July 14, 2022
Filing Date:
November 12, 2021
Export Citation:
Assignee:
AKTTYVA THERAPEUTICS INC (US)
International Classes:
C12Q1/48; C12N9/12; G01N33/573
Domestic Patent References:
| WO2003048340A2 | 2003-06-12 |
Foreign References:
| US20040091872A1 | 2004-05-13 |
Other References:
HSU, T ET AL.: "Active roles of dysfunctional vascular endothelium in fibrosis and cancer", JOURNAL OF BIOMEDICAL SCIENCE, vol. 26, 28 October 2019 (2019-10-28), pages 1 - 12, XP055957639, DOI: 10.1186/s12929-019-0580-3
CUI, X ET AL.: "The potential role of leflunomide in inhibiting vascular fibrosis by down-regulating type-II macrophages in Takayasu's arteritis", CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, vol. 38, no. 2, 14 January 2020 (2020-01-14), pages 69 - 78, XP055957645
CUI, X ET AL.: "The potential role of leflunomide in inhibiting vascular fibrosis by down-regulating type-II macrophages in Takayasu's arteritis", CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, vol. 38, no. 2, 14 January 2020 (2020-01-14), pages 69 - 78, XP055957645
Attorney, Agent or Firm:
MCCARTY, Catherine, M. (US)
Download PDF:
Previous Patent: MULTI RADAR OBJECT DETECTION
Next Patent: REFINED USES OF GABAA RECEPTOR MODULATORS IN TREATMENT OF FRAGILE X SYNDROME
Next Patent: REFINED USES OF GABAA RECEPTOR MODULATORS IN TREATMENT OF FRAGILE X SYNDROME